Chimin Health Management Co (603222) Fair Value & Analysis
Healthcare · CN · Market cap 4.3B CNY
Analysis
Chimin Health Management Co (603222) currently trades at ¥7.89, while our model-based Fair Value estimate is ¥10.45 — implying the stock looks roughly 32.4% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells vitro diagnostic products and provides medical services in China and internationally. The company provides non-PVC double-tube double-valve, single-tube single-valve, and single-tube double-valve soft bags; plastic bottles; and other packaging forms. It also offers medical instruments, including safety syringes, safety injection needles, sterile syringes, dispensers, insulin syringes, infusion sets, precision filter infusion sets, and other products. In addition, the company provides in vitro diagnostics products, such as clinical chemical diagnostic, immunological diagnostic, blood testing, rapid diagnostic, and enzyme-linked immunological diagnostic reagents; laboratory instruments; and in vitro diagnostic medical products, as well as FOB fecal occult blood automated immunoassay monitoring and pylori Helicobacter detection kits. Further, it offers hemodialysis series produ…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.